Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders. In September 2008, the Company entered into a lease for laboratory space for a small scale research facility in San Diego, Calif. This facility will complement Amicus' core research and development activities in New Jersey, while allowing closer access to the significant scientific and biotechnology resources in the San Diego community.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended September 30, 2008, was $8.2 million as compared to $10.3 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended September 30, 2008, was $6.6 million as compared to $9.2 million in the same period in 2007.

Amicus recorded revenue during the third quarter of 20
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 ... of leading Immunologists, Principle Investigators, scientists in the ... J Malemud, Professor at Case Western Reserve University ... his keynote address on “The effects of ... production of matrix metalloproteinase-9”. Arya Biragyn, a Senior ...
(Date:7/29/2014)... 2014 SoundConnect , an ... is proud to announce the strategic additions of ... their Boston, Charleston and Atlanta offices. SoundConnect’s ... demand for hosted solutions, collaboration and mobility that ... cost. , SoundConnect was founded in 2004, with ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
Breaking Biology Technology:Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4
... Calif., Aug. 11 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... second quarter of 2008 ended June 30 were,$3,027,497 ... for the second,quarter of 2007. Revenues for the ... from the previous year., The significant revenue ...
... Calif., Aug. 11 Telik, Inc.,(Nasdaq: TELK ) reported ... the second quarter ended June 30, 2008, compared with a ... comparable period in 2007. The,$13.6 million net loss for the ... charge related to auction rate securities, which,is reflected in interest ...
... least half of shipments by the end of ... today announced that it will begin shipment of ... to U.S. customers,for the 2008-2009 influenza season. The ... Evaluation and Research (CBER) released the,first lots of ...
Cached Biology Technology:Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 2Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 5Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 6Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 7Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 8Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 9Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 2GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 4
(Date:7/30/2014)... A group of researchers from the University of Helsinki ... experimentally to reproduce in mice morphological changes which have ... gradual modifications in the embryonic development of mice teeth, ... morphologically are very similar to those observed in the ... millions of years ago. , To modify the ...
(Date:7/30/2014)... is pleased to announce its new relationship with the ... and CINP will partner to publish International Journal ... open-access journal. , Alan Frazer, Editor-in-Chief of IJNP ... expertise of OUP will further facilitate the goal for ... very leading journals within neuropsychopharmacology. The conversion of the ...
(Date:7/30/2014)... $1 million from the Cornelia Cogswell Rossi Foundation to ... , The newly established Connie Cogswell Rossi ... a greater breadth and depth of knowledge of neurobehavioral ... of research to improve human health. , The new ... Laboratory and its external partners, supporting research to enhance ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... (August 2, 2013) In a new observational study ... researchers looked at the association of grape consumption, in ... raisins and 100% grape juice with the diet ... children and adults. Their findings suggest that, among adults ...
... University of Toronto Engineering professor Ben Hatton is turning ... the energy leaks from windows. In an article in ... his colleagues at Harvard University describe a novel process to ... buildings cool during the summer. Their "bio-inspired approach to ...
... . . . By substituting lignin for ... have developed a process that requires fewer steps and ... ReNEW-PRO, is a low-cost lithium-ion battery anode made inexpensively ... pulp and paper industry. ReNEW-PRO was developed in collaboration ...
Cached Biology News:Grape consumption associated with healthier eating patterns in US children and adults 2Bio-inspired design may lead to more energy efficient windows 2August 2013 story tips from Oak Ridge National Laboratory 2
...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... derived from the Spodoptera frugiperda Sf21 cell line ... transfections, plaque assays, virus production, and protein expression. ... optimizes recovery of viable cells after thawing. They ... Cell Medium and can also be grown in ...
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
Biology Products: